{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:04:23Z","timestamp":1792087463975,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["HRA-POR-2013-236"],"award-info":[{"award-number":["HRA-POR-2013-236"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023331","name":"LEO Pharma A\/S","doi-asserted-by":"publisher","award":["IIS FASLN29162"],"award-info":[{"award-number":["IIS FASLN29162"]}],"id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","thrombosisresearch.com","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.thromres.2024.109251","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T07:29:17Z","timestamp":1735543757000},"page":"109251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Chemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis"],"prefix":"10.1016","volume":"246","author":[{"given":"M.P.","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"O'Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Marchocki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"O'Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Abu","family":"Saadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.A.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.thromres.2024.109251_bb0005","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/ATVBAHA.123.318779","article-title":"Updates in the incidence, pathogenesis, and Management of Cancer and Venous Thromboembolism","volume":"43","author":"Girardi","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"14","key":"10.1016\/j.thromres.2024.109251_bb0010","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2024.109251_bb0015","doi-asserted-by":"crossref","unstructured":"Riondino S, Ferroni P, Zanzotto FM, Roselli M, Guadagni F. Predicting VTE in Cancer patients: candidate biomarkers and risk assessment models. Cancers (Basel) 2019Jan 15;11(1):95. doi:https:\/\/doi.org\/10.3390\/cancers11010095.","DOI":"10.3390\/cancers11010095"},{"issue":"5","key":"10.1016\/j.thromres.2024.109251_bb0020","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.thromres.2013.09.016","article-title":"Tumour expression of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk","volume":"132","author":"Abu Saadeh","year":"2013","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.thromres.2024.109251_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100123","article-title":"Mechanisms of cancer-associated thrombosis","volume":"7","author":"Hisada","year":"2023","journal-title":"Res Pract Thromb Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.109251_bb0030","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0049-3848(20)30405-9","article-title":"Genetic and epigenetic regulation of cancer coagulome - lessons from heterogeneity of cancer cell populations","volume":"191","author":"Tawil","year":"2020","journal-title":"Thromb. Res."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2024.109251_bb0035","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/S0049-3848(12)70022-1","article-title":"The protein C pathway in cancer metastasis","volume":"129","author":"Spek","year":"2012","journal-title":"Thromb. Res."},{"issue":"8","key":"10.1016\/j.thromres.2024.109251_bb0040","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0040-1718927","article-title":"Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: Risk Factors and Prevention","volume":"47","author":"Prandoni","year":"2021","journal-title":"Semin Thromb Hemost."},{"key":"10.1016\/j.thromres.2024.109251_bb0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2021.01.012","article-title":"Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-the role of the activated protein C pathway","volume":"200","author":"Ward","year":"2021","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.thromres.2024.109251_bb0050","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Electronic address: clinicalguidelines@esmo.org. Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.thromres.2024.109251_bb0055","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/rth2.12342","article-title":"A risk score for prediction of venous thromboembolism in gynecologic cancer: the Thrombogyn score","volume":"4","author":"Norris","year":"2020","journal-title":"Res Pract Thromb Haemost."},{"key":"10.1016\/j.thromres.2024.109251_bb0060","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ygyno.2009.10.050","article-title":"The new FIGO staging systems for cancers of the vulva, cervix, endometrium and sarcomas","volume":"115","author":"Mutch","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.thromres.2024.109251_bb0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3802\/jgo.2015.26.2.87","article-title":"FIGO\u2019s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication","volume":"26","author":"Prat J; FIGO Committee on Gynecologic Oncology","year":"2015","journal-title":"J. Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.thromres.2024.109251_bb0070","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000205234","article-title":"Rapid physiological coagulation method in determination of fibrinogen","volume":"17","author":"Clauss","year":"1957","journal-title":"Acta Haematol."},{"issue":"4","key":"10.1016\/j.thromres.2024.109251_bb0075","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.thromres.2024.109251_bb0080","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1538-7836.2005.01430.x","article-title":"(2005), determinants of the APTT- and ETP-based APC sensitivity tests","volume":"3","author":"De Visser","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109251_bb0085","doi-asserted-by":"crossref","unstructured":"Norris LA, Martin FA, O'Toole SA, Saadeh FA, Gleeson N. PO-24 - Determinants of thrombin generation in gynaecological malignancies. Thromb Res. 2016 Apr;140 Suppl 1:S185. doi:https:\/\/doi.org\/10.1016\/S0049-3848(16)30157-8. Epub 2016 Apr 8. PMID: 27161714.","DOI":"10.1016\/S0049-3848(16)30157-8"},{"issue":"6","key":"10.1016\/j.thromres.2024.109251_bb0090","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jtha.2023.02.029","article-title":"Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity","volume":"21","author":"Falanga","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109251_bb0095","doi-asserted-by":"crossref","unstructured":"Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, Larsen AK, Elalamy I; COMPASS\u2013CAT Working Group. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian Cancer: the prospective COMPASS-Cancer-associated thrombosis study. Oncologist 2017Oct;22(10):1222\u20131231. doi:https:\/\/doi.org\/10.1634\/theoncologist.2016-0414.","DOI":"10.1634\/theoncologist.2016-0414"},{"key":"10.1016\/j.thromres.2024.109251_bb0100","doi-asserted-by":"crossref","unstructured":"Pabinger, I., van Es, N., Heinze, G., Posch, F., Riedl, J., Reitter, E.M., Di Nisio, M., Cesarman-Maus, G., Kraaijpoel, N., Zielinski, C.C. and B\u00fcller, H.R., 2018. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018 Jul;5(7):e289-e298. Doi:10.1016\/S2352-3026(18)30063-2. Erratum in: lancet Haematol. 2018 Aug;5(8):e332. doi:https:\/\/doi.org\/10.1016\/S2352-3026(18)30095-4.","DOI":"10.1016\/S2352-3026(18)30063-2"},{"issue":"3","key":"10.1016\/j.thromres.2024.109251_bb0105","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1538-7836.2009.03711.x","article-title":"APC resistance: biological basis and acquired influences","volume":"8","author":"Castoldi","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109251_bb0110","article-title":"Thrombin generation markers as predictors of Cancer-associated venous thromboembolism: A systematic review","author":"Gyldenholm","year":"2023","journal-title":"Semin. Thromb. Hemost."},{"issue":"15","key":"10.1016\/j.thromres.2024.109251_bb0115","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and thrombosis study","volume":"29","author":"Ay","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.thromres.2024.109251_bb0120","doi-asserted-by":"crossref","unstructured":"Ferroni P, Martini F, Portarena I, et al. Early changes of a novel APC-dependent thrombin generation assay during chemotherapy independently predict venous thromboembolismin cancer patients\u2013a pilot study. Support Cancer Care. 2012Nov;20(11):2713\u201320. doi:https:\/\/doi.org\/10.1007\/s00520-012-1391-1.","DOI":"10.1007\/s00520-012-1391-1"},{"issue":"2\u20134","key":"10.1016\/j.thromres.2024.109251_bb0125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000324166","article-title":"Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients","volume":"37","author":"Mukherjee","year":"2010","journal-title":"Pathophysiol. Haemost. Thromb."},{"issue":"5","key":"10.1016\/j.thromres.2024.109251_bb0130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/ijc.28104","article-title":"2013. Impact of chemotherapy on activated protein C-dependent thrombin generation\u2014association with VTE occurrence","volume":"133","author":"Roselli","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.thromres.2024.109251_bb0135","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1055\/a-1801-2055","article-title":"Circulating Thrombomodulin: release mechanisms, measurements, and levels in diseases and medical procedures","volume":"6","author":"Boron","year":"2022","journal-title":"TH Open."},{"issue":"6","key":"10.1016\/j.thromres.2024.109251_bb0140","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1172\/JCI112225","article-title":"1985. Thrombomodulin is present in human plasma and urine","volume":"76","author":"Ishii","year":"1985","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.thromres.2024.109251_bb0145","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1538-7836.2005.01267.x","article-title":"Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma","volume":"3","author":"Ohlin","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"28","key":"10.1016\/j.thromres.2024.109251_bb0150","doi-asserted-by":"crossref","first-page":"16603","DOI":"10.1074\/jbc.271.28.16603","article-title":"TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex","volume":"271","author":"Bajzar","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.thromres.2024.109251_bb0155","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.2019004267","article-title":"A high-fat diet delays plasmin generation in a thrombomodulin-dependent manner in mice","volume":"135","author":"Miszta","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2024.109251_bb0160","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1172\/JCI116151","article-title":"Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. A potential rapid mechanism for modulation of coagulation","volume":"90","author":"Glaser","year":"1992","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.thromres.2024.109251_bb0165","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2012.09134.x","article-title":"Elevated factor VIII levels and risk of venous thrombosis","volume":"157","author":"Jenkins","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2024.109251_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis","author":"Koster","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2024.109251_bb0175","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1161\/ATVBAHA.109.190827","article-title":"High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study","volume":"29","author":"Vormittag","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.thromres.2024.109251_bb0180","doi-asserted-by":"crossref","unstructured":"O'Donnell J, Mumford AD, Manning RA, Laffan MA. Marked elevation of thrombin generation in patients with elevated FVIII:C and venous thromboembolism. Br. J. Haematol. 2001Dec;115(3):687\u201391. doi:https:\/\/doi.org\/10.1046\/j.1365-2141.2001.03146.x.","DOI":"10.1046\/j.1365-2141.2001.03146.x"},{"issue":"8","key":"10.1016\/j.thromres.2024.109251_bb0185","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1111\/jth.15773","article-title":"The role of VWF\/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies","volume":"20","author":"Comerford","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2024.109251_bb0190","doi-asserted-by":"crossref","unstructured":"Otero, R.; Solier-L\u00f3pez, A.; S\u00e1nchez-L\u00f3pez, V.; Oto, J.; Arellano,E.; Mar\u00edn, S.; Jara-Palomares, L.; El\u00edas, T.; Asencio, M.I.; Blasco-Esquivias, I.; et al. Biomarkers of venous thromboembolism recurrence after discontinuation of low molecular weight heparin treatment for Cancer-associated thrombosis (HISPALIS-study). Cancers (Basel) 2022Jun 2;14(11):2771. doi:https:\/\/doi.org\/10.3390\/cancers14112771.","DOI":"10.3390\/cancers14112771"},{"issue":"1","key":"10.1016\/j.thromres.2024.109251_bb0195","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/hematology.2019000025","article-title":"Update from the laboratory: mechanistic studies of pathways of cancer-associated venous thrombosis using mouse models","volume":"2019","author":"Hisada","year":"2019","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"2","key":"10.1016\/j.thromres.2024.109251_bb0200","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/rth2.12091","article-title":"2018. Factor V levels and risk of venous thrombosis: the MEGA case-control study","volume":"2","author":"Rietveld","year":"2018","journal-title":"Res Pract Thromb Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2024.109251_bb0205","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1055\/s-0038-1656549","article-title":"Factor V has anticoagulant activity in plasma in the presence of TFPI\u03b1: difference between FV1 and FV2","volume":"118","author":"van Doorn","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"Suppl.1","key":"10.1016\/j.thromres.2024.109251_bb0210","first-page":"630","article-title":"Expression of coagulation proteases from the activated protein C pathway in ovarian Tumours. Research practice","volume":"1","author":"Spourquet","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"2020","key":"10.1016\/j.thromres.2024.109251_bb0215","article-title":"Identification of F5 as a prognostic biomarker in patients with gastric Cancer","volume":"27","author":"Liu","year":"2020","journal-title":"Biomed. Res. Int."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824003839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384824003839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T23:31:46Z","timestamp":1740353506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384824003839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"alternative-id":["S0049384824003839"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109251","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy alters thrombomodulin and factor VIIIc expression resulting in acquired activated protein C resistance and enhanced thrombin generation in cancer associated thrombosis","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2024.109251","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109251"}}